about
Reducing the probability of false positive research findings by pre-publication validation - experience with a large multiple sclerosis databaseMagnetic resonance imaging as a surrogate outcome for multiple sclerosis relapsesPlacebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case dataNeuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells.Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β.Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Clinical predictors of early second event in patients with clinically isolated syndrome.Fingolimod after natalizumab and the risk of short-term relapse.Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.Burden of risk variants correlates with phenotype of multiple sclerosis.The relationship between enhanced plaques with Gadovist and Magnevist contrast brain magnetic resonance imaging and the neurological deficit in the acute phase of relapsing remitting multiple sclerosis.Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.Gender effects on treatment response to interferon-beta in multiple sclerosis.Androgen-Induced Immunosuppression.
P2860
Q24288959-FB3BE87A-A265-405C-A8BC-93A458D0DCCAQ24288978-90A2E2F2-2ABC-47A8-B24F-A29409CD458FQ30000824-CC1BCADD-0348-4745-86DB-269620600C5DQ30576477-2FBFF573-B499-4942-A8D3-6315626222BCQ33485522-76752B58-52E4-4667-8968-5E33AB6EEC31Q33765140-67436424-2820-42FE-98C1-0179B1F6A7FAQ34020232-59F644FE-BB21-45ED-B3D0-62F3C92AB13FQ34478828-8DD3E3F2-0458-4E75-8B66-1583292D7F23Q37255947-6ED04980-F41D-4F2E-A1AF-F22832C1478CQ37725909-585E4FD2-6761-4067-ADC3-50CC99784E7BQ38087504-CECFB518-DD0B-4D46-AE4F-4898936CAB97Q38632074-4E95B70A-2D52-4550-AC74-71AE051744DBQ41757025-466CB79D-B993-4633-B2B5-6A2F8B18D5E3Q42905723-A24949D8-B88D-4AB5-94D1-62F37FF83108Q43727375-D9871EAC-ACF1-4D36-931A-022004643B92Q48922719-E7010D05-38C0-4C42-85C1-F5A14A4176BAQ50111623-D58EC9E2-F404-434E-A6A2-FDFB5F754AE7Q50945427-24E42A77-A497-4121-A1BD-583E13A9D78AQ51114281-B60FAC27-AFA1-4DF8-9525-563D4E123FECQ55357541-912733BA-3612-4555-AC57-F33422782350
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Predictors of relapse rate in MS clinical trials.
@en
Predictors of relapse rate in MS clinical trials.
@nl
type
label
Predictors of relapse rate in MS clinical trials.
@en
Predictors of relapse rate in MS clinical trials.
@nl
prefLabel
Predictors of relapse rate in MS clinical trials.
@en
Predictors of relapse rate in MS clinical trials.
@nl
P2093
P1433
P1476
Predictors of relapse rate in MS clinical trials.
@en
P2093
L Heigenhauser
Sylvia Lawry Centre for MS Research
P304
P356
10.1212/01.WNL.0000187122.71735.1F
P407
P50
P577
2005-12-01T00:00:00Z